XML 48 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
DEBT (Details Narrative)
1 Months Ended 9 Months Ended 12 Months Ended
May 12, 2017
USD ($)
May 05, 2017
USD ($)
Apr. 10, 2017
USD ($)
Mar. 16, 2017
USD ($)
Aug. 04, 2016
USD ($)
shares
May 31, 2018
USD ($)
Mar. 16, 2018
USD ($)
Feb. 19, 2018
USD ($)
Jan. 18, 2018
USD ($)
May 16, 2017
USD ($)
Mar. 23, 2017
USD ($)
shares
Mar. 20, 2017
USD ($)
Nov. 16, 2015
USD ($)
Sep. 30, 2018
USD ($)
shares
Sep. 30, 2018
CAD ($)
shares
Dec. 31, 2017
USD ($)
Apr. 02, 2018
USD ($)
Mar. 31, 2018
USD ($)
Nov. 16, 2017
USD ($)
Jul. 31, 2017
USD ($)
Jan. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Nov. 30, 2016
USD ($)
Oct. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Sep. 13, 2016
USD ($)
Debt outstanding amount                           $ 3,078,442                        
Accrued interest                           364,479                        
Debt discount                           3,216,000   $ 3,350,000                    
Amortization of debt discount               $ 392,272           2,072,740   360,890                    
Cash received                           $ 40,858                        
CEO [Member]                                                    
Percentage of wholly-owned subsidiary shares                           51.00%                        
TFF [Member]                                                    
Short term debt borrowing capacity                           $ 15,000,000                        
Libor rate description                           <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i) all lending in U.S. dollars is the one-month LIBOR plus six (6%) percent margin; and (ii) for all lending in Euro, the one-month Euribor Rate plus six (6%) percent per annum, commencing June 1, 2018.</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i) all lending in U.S. dollars is the one-month LIBOR plus six (6%) percent margin; and (ii) for all lending in Euro, the one-month Euribor Rate plus six (6%) percent per annum, commencing June 1, 2018.</font></p>                      
Trade Facility Agreements [Member]                                                    
Debt outstanding amount                                   $ 5,866,910                
Payment of interest and principal           $ 1,162,200                                        
SkyPharm [Member]                                                    
Short term debt borrowing capacity                           $ 313,794                        
Amount withdraw from related party                           5,656,323                        
Accrued interest                           526,656                        
SkyPharm [Member] | MediHelm S.A. [Member]                                                    
Amortization of debt discount                           66,944   69,269                    
Origination fees                           $ 137,063                        
SkyPharm [Member] | Trade Facility Agreements [Member]                                                    
Short term debt borrowing capacity $ 2,464,000                                                  
Description for the repayment The total facility will be calculated as 95% of the agreed upon value of Decahedrons receivables.                                                  
Term of credit facility 12 months                                                  
Credit facility origination fee, percentage 2.00%                                                  
Monthly credit fee, percentage 1.00%                                                  
Additional gain on settlement of debt $ 332,640                                                  
Maximum aggregate amount supplement deed                   $ 18,480,000                                
SkyPharm [Member] | Trade Facility Agreements [Member] | Minimum [Member]                                                    
Short term debt borrowing capacity                                     $ 2,464,000              
SkyPharm [Member] | Trade Facility Agreements [Member] | Maximum [Member]                                                    
Short term debt borrowing capacity                                     $ 7,392,000              
On April 18, 2018 [Member]                                                    
Maturity date                           Dec. 31, 2021 Dec. 31, 2021                      
Libor rate description                           <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Additionally, the interest rate was amended such that the interest rate for all advances is 4% plus the 3-Month Libor rate.</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Additionally, the interest rate was amended such that the interest rate for all advances is 4% plus the 3-Month Libor rate.</font></p>                      
Gain on debt settlement                           $ 23,607                        
Loan Facility July 6, 2017 [Member]                                                    
Fees forgiven related to advance                           40,000                        
Loan Agreement [Member] | Panagiotis Drakopoulos [Member]                                                    
Short term debt borrowing capacity                         $ 43,624                          
Interest rate                         6.00%                          
Maturity date                         Nov. 15, 2016                          
Debt outstanding amount                           15,109   20,437                    
Accrued interest                           3,360   2,477                    
Loan Agreement 2 [Member]                                                    
Short term debt borrowing capacity             $ 1,743,300                                      
Interest rate             4.70%                                      
Maturity date             Mar. 18, 2019                                      
Debt outstanding amount                           1,848,000                        
Accrued interest                           44,001                        
Repayment of debt                           11,622                        
Bridge Loans [Member] | SkyPharm [Member]                                                    
Short term debt borrowing capacity   $ 34,745   $ 50,000               $ 120,220                            
Interest rate   10.00%   10.00%               10.00%                            
Maturity date   Sep. 30, 2017   Apr. 16, 2017               Apr. 20, 2017                            
Amended maturity date       May 16, 2017               May 20, 2017                            
Debt outstanding amount       $ 50,000               $ 106,542   34,745                        
Accrued interest       $ 14,138               16,857   3,906                        
Gain on debt settlement                       19,909                            
Additional gain on settlement of debt                       4,718                            
Loan fixed payoff amount                       $ 106,542                            
Loan Facility Agreement [Member]                                                    
Debt discount                           191,034                        
Amortization of debt discount                           50,363                        
Unamortized debt discount                           23,639                        
Total amortized                           114,158                        
Loan Facility Agreement [Member] | SkyPharm [Member]                                                    
Short term debt borrowing capacity         $ 1,292,769                                          
Interest rate         10.00%                                          
Description for the repayment         <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The amounts owed under the Loan Facility shall be repayable upon the earlier of (i) three months following the demand of the lender; or (ii) August 31, 2018. No prepayment is permitted pursuant to the terms of the Loan Facility</font></p>                                          
Loan Facility Agreement [Member] | Grigorios Siokas [Member] | Synthesis facility agreement [Member]                                                    
Common stock shares reserved | shares         10,000,000                                          
Loan Agreement 3 [Member]                                                    
Short term debt borrowing capacity                                 $ 0                  
Debt outstanding amount                           5,811                        
Second amendment to loan facility agreement [Member] | SkyPharm [Member]                                                    
Short term debt borrowing capacity                     $ 2,664,960         $ 70,000       $ 382,327 $ 155,516 $ 452,471 $ 250,000 $ 100,000 $ 174,000  
Interest rate                     10.00%                              
Maturity date                     Aug. 04, 2016                              
Description for the repayment                     <p style="margin: 0">The amounts owed under the A&R Loan Facility shall be repayable upon the earlier of (i) seventy five days following the demand of the Lender; or (ii) August 31, 2018.</p>                              
Common stock shares reserved | shares                     1,000,000                              
Amendment to loan facility agreement [Member] | SkyPharm [Member]                                                    
Short term debt borrowing capacity                                                   $ 1,533,020
Debt outstanding amount                                                   $ 240,251
Loan Agreement 1 [Member]                                                    
Short term debt borrowing capacity                 $ 87,165                                  
Interest rate                 6.50%                                  
Maturity date                 Jan. 17, 2019                                  
Loan Agreement 1 [Member] | Grigorios Siokas [Member]                                                    
Debt outstanding amount                           92,400                        
Accrued interest                           $ 2,032                        
Decahedron [Member] | SkyPharm [Member] | Trade Facility Agreements [Member]                                                    
Short term debt borrowing capacity     $ 3,388,000                                              
Description for the repayment     The total facility will be calculated as 95% of the agreed upon value of Decahedrons receivables                                              
Term of credit facility     12 months                                              
Credit facility origination fee, percentage     2.00%                                              
Monthly credit fee, percentage     1.00%                                              
Marathon [Member]                                                    
Distribution and equity acquisition agreement, description                           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As consideration for its services, Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in Common Shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As consideration for its services, Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in Common Shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000.</font></p>                      
Settlement amount                           $ 1,554,590                        
Cash received                             $ 2,000,000                      
Shares issued for settlement of debt | shares                           295,960 295,960